REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced that Daniel Florin has joined its Board of Directors.
Mr. Florin has been serving as Executive Vice President at Zimmer Biomet Holdings Inc. since July 2019 (NYSE: ZBH). Previously, he served as Executive Vice President and Chief Financial Officer of Zimmer Biomet. In addition, he served as Interim Chief Executive Officer of Zimmer Biomet from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Senior Vice President and Chief Financial Officer of Biomet, Inc. until Biomet, Inc. merged with Zimmer, Inc. and became Zimmer Biomet Holdings Inc. Prior to working at Biomet, he held various roles at Boston Scientific Corporation, C.R. Bard Inc. and Deloitte & Touche, LLP.
“I am truly excited to join the Pulmonx board and be part of this experienced team,” said Mr. Florin. “I look forward to helping Pulmonx continue the important work of bringing minimally invasive solutions to patients suffering with severe emphysema, a form of COPD.”
“I am very pleased Dan has agreed to join the Pulmonx Board of Directors,” said Glen French, President and Chief Executive Officer. “His financial and operating experience will be incredibly beneficial to Pulmonx as we continue our growth in the coming years. I look forward to working with and learning from him.”
About Pulmonx
Pulmonx Corporation is a commercial-stage medical device company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. We have a compelling body of clinical evidence with over 100 scientific articles published regarding the clinical benefits of Zephyr Valves. Multiple randomized controlled clinical trials have demonstrated that patients selected with the Chartis System and successfully treated with Zephyr Valves have shown statistically and clinically significant improvements in lung function, exercise capacity and quality of life compared to medical management alone. In June 2018, Pulmonx received pre-market approval through the FDA’s ‘breakthrough device’ pathway to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available in more than 25 countries, with over 76,000 valves used to treat more than 19,000 patients. For more information, visit www.MyLungsMyLife.com.
P0976EN_A